GeneMind Biosciences secured NMPA registration for its SURFSeq 5000 Dx sequencer, enabling deployment in China’s clinical market for oncology, inherited disease, reproductive health, and infectious diseases. The company positioned the instrument as a high-throughput benchtop platform generating up to 2.2 Tb of data per run. Separately, Guardant Health and Nuvalent announced a multi-year strategic collaboration to develop oncology companion diagnostics using Guardant’s tissue and liquid biopsy portfolio. The companies plan to support Nuvalent’s global clinical studies and pursue companion diagnostic opportunities tied to investigational candidates. Together, the updates reflect two critical buildouts: expanding clinical sequencing capacity domestically in China, and pairing molecular diagnostics with oncology pipeline development in global trials.